Rachel A Silverman1,2, Ingrid A Beck3, Catherine Kiptinness2, Molly Levine3, Ross Milne3, Christine J McGrath2, Steve Bii3, Barbra A Richardson2,4, Grace John-Stewart1,2,5,6, Bhavna Chohan2, Samah R Sakr7, James N Kiarie8, Lisa M Frenkel2,3,5,6,9, Michael H Chung1,2,5. 1. Department of Epidemiology, University of Washington, Seattle. 2. Department of Global Health, University of Washington, Seattle. 3. Seattle Children's Research Institute, Washington. 4. Department of Biostatistics, University of Washington, Seattle. 5. Department of Medicine, University of Washington, Seattle. 6. Department of Pediatrics, University of Washington, Seattle. 7. Coptic Hospital, Nairobi. 8. Department of Obstetrics and Gynaecology, University of Nairobi, Kenya. 9. Department of Laboratory Medicine, University of Washington, Seattle.
Abstract
Background: Pre-antiretroviral-treatment drug resistance (PDR) is a predictor of human immunodeficiency virus (HIV) treatment failure. We determined PDR prevalence and correlates in a Kenyan cohort. Methods: We conducted a cross-sectional analysis of antiretroviral (ARV) treatment-eligible HIV-infected participants. PDR was defined as ≥2% mutant frequency in a participant's HIV quasispecies at pol codons K103N, Y181C, G190A, M184 V, or K65R by oligonucleotide ligation assay and Illumina sequencing. PDR prevalence was calculated by demographics and codon, stratifying by prior ARV experience. Poisson regression was used to estimate prevalence ratios. Results: PDR prevalences (95% confidence interval [CI]) in 815 ARV-naive adults, 136 ARV-experienced adults, and 36 predominantly ARV-naive children were 9.4% (7.5%-11.7%), 12.5% (7.5%-19.3%), and 2.8% (0.1%-14.5%), respectively. Median mutant frequency within an individual's HIV quasispecies was 67%. PDR prevalence in ARV-naive women 18-24 years old was 21.9% (9.3%-40.0%). Only age in females associated with PDR: A 5-year age decrease was associated with adjusted PDR prevalence ratio 1.20 (95% CI, 1.06-1.36; P = .004). Conclusions: The high PDR prevalence may warrant resistance testing and/or alternative ARVs in high HIV prevalence settings, with attention to young women, likely to have recent infection and higher rates of resistance. Clinical Trials Registration: NCT01898754.
Background: Pre-antiretroviral-treatment drug resistance (PDR) is a predictor of human immunodeficiency virus (HIV) treatment failure. We determined PDR prevalence and correlates in a Kenyan cohort. Methods: We conducted a cross-sectional analysis of antiretroviral (ARV) treatment-eligible HIV-infectedparticipants. PDR was defined as ≥2% mutant frequency in a participant's HIV quasispecies at pol codons K103N, Y181C, G190A, M184 V, or K65R by oligonucleotide ligation assay and Illumina sequencing. PDR prevalence was calculated by demographics and codon, stratifying by prior ARV experience. Poisson regression was used to estimate prevalence ratios. Results: PDR prevalences (95% confidence interval [CI]) in 815 ARV-naive adults, 136 ARV-experienced adults, and 36 predominantly ARV-naive children were 9.4% (7.5%-11.7%), 12.5% (7.5%-19.3%), and 2.8% (0.1%-14.5%), respectively. Median mutant frequency within an individual's HIV quasispecies was 67%. PDR prevalence in ARV-naive women 18-24 years old was 21.9% (9.3%-40.0%). Only age in females associated with PDR: A 5-year age decrease was associated with adjusted PDR prevalence ratio 1.20 (95% CI, 1.06-1.36; P = .004). Conclusions: The high PDR prevalence may warrant resistance testing and/or alternative ARVs in high HIV prevalence settings, with attention to young women, likely to have recent infection and higher rates of resistance. Clinical Trials Registration: NCT01898754.
Authors: Fiona E Lyons; Suzie Coughlan; Christina M Byrne; Susan M Hopkins; William W Hall; Fiona M Mulcahy Journal: AIDS Date: 2005-01-03 Impact factor: 4.177
Authors: Ingrid A Beck; Wenjie Deng; Rachel Payant; Robert Hall; Roger E Bumgarner; James I Mullins; Lisa M Frenkel Journal: J Clin Microbiol Date: 2014-04-16 Impact factor: 5.948
Authors: Michael H Chung; Ingrid A Beck; Sandra Dross; Kenneth Tapia; James N Kiarie; Barbra A Richardson; Julie Overbaugh; Samah R Sakr; Grace C John-Stewart; Lisa M Frenkel Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: Lancet Infect Dis Date: 2011-07-27 Impact factor: 25.071
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman Journal: J Virol Date: 2008-03-19 Impact factor: 5.103
Authors: Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio Journal: Lancet Date: 2012-07-23 Impact factor: 79.321
Authors: Wan-Lin Yang; Roger D Kouyos; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Alexandra U Scherrer; Mohaned Shilaih; Trevor Hinkley; Christos Petropoulos; Sebastian Bonhoeffer; Huldrych F Günthard Journal: PLoS Pathog Date: 2015-03-23 Impact factor: 6.823
Authors: Benjamin Chimukangara; Ayesha B M Kharsany; Richard J Lessells; Kogieleum Naidoo; Soo-Yon Rhee; Justen Manasa; Tiago Gräf; Lara Lewis; Cherie Cawood; David Khanyile; Karidia Diallo; Kassahun A Ayalew; Robert W Shafer; Gillian Hunt; Deenan Pillay; Salim Karim Abdool; Tulio de Oliveira Journal: AIDS Res Hum Retroviruses Date: 2019-01-07 Impact factor: 2.205
Authors: Ross S Milne; Rachel A Silverman; Ingrid A Beck; Jennifer Mckernan-Mullin; Wenjie Deng; Thomas R Sibley; Sandra Dross; James N Kiarie; Samah R Sakr; Robert W Coombs; Michael H Chung; Lisa M Frenkel Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Ceejay L Boyce; Tatiana Sils; Daisy Ko; Annie Wong-On-Wing; Ingrid A Beck; Sheila M Styrchak; Patricia DeMarrais; Camlin Tierney; Lynda Stranix-Chibanda; Patricia M Flynn; Taha E Taha; Maxensia Owor; Mary Glenn Fowler; Lisa M Frenkel Journal: Clin Infect Dis Date: 2022-06-10 Impact factor: 20.999
Authors: Ingrid A Beck; Molly Levine; Christine J McGrath; Steve Bii; Ross S Milne; James M Kingoo; Isaac So; Nina Andersen; Sandra Dross; Robert W Coombs; James Kiarie; Bhavna Chohan; Samah R Sakr; Michael H Chung; Lisa M Frenkel Journal: EClinicalMedicine Date: 2020-01-14
Authors: Rachel A Silverman; Grace C John-Stewart; Ingrid A Beck; Ross Milne; Catherine Kiptinness; Christine J McGrath; Barbra A Richardson; Bhavna Chohan; Samah R Sakr; Lisa M Frenkel; Michael H Chung Journal: PLoS One Date: 2019-10-04 Impact factor: 3.240